Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomized phase 3 trial. Lancet Rheumatol. 2022 Mar 1;4(3):e208-19.
Coon CD, Bokowy KL, Horblyuk R, Zisman RS, McLeod LD, Brown MT. The development and initial assessment of the strategy and leadership systems capability evaluation survey. Health Care Manag (Frederick). 2012 Oct 1;31(4):332-41.
Watson V, Ryan M. Exploring preference anomalies in double bounded contingent valuation. J Health Econ. 2007 May 1;26(3):463-82. doi: 10.1016/j.jhealeco.2006.10.009